LIGHTS specifically addresses early phase medicinal chemistry issues that can critically influence the time schedule for obtaining an investigational drug candidate. Nevertheless it is also expected as products of our project that potential drug candidate(s) with high quality in vitro activity profile can be obtained ready for in vivo pharmacology profiling.

In particular LIGHTS objectives are:
 


1. Derivation of small-ligand libraries with ligands design to bind to the Thymidylate synthase monomer /monomer interface affecting dimer formation and TS- TSmRNA interactions.

2. Validation of the integrated, multidisciplinary drug design strategy necessary to achieve objective 1, which poses a highly challenging design problem. The strategy including systems pathway studies, protein residue SH and X -labelling to identify low-affinity ligands, peptide mimetic design, and filtering for ADME properties.

3. Identification of small-ligands identified in a chemical-biology approach as effective perturbing agents to investigate the mechanism of resistance against a panel of cis-platinum resistant ovarian carcinoma cell lines.

4. Provide potential drug candidate(s) with new mechanism of action for further development as safer therapeutic agent(s) for the treatment of ovarian carcinoma.

info@lights-eu.org
MANAGEMENT
Coordination
Committee
Guest scientists
Participants
OBJECTIVE
Synopsis
Project summary
PARTNERS
WORK PACKAGES
Overview
PROJECT MEETINGS
 
LIGands to interfere with Human TS - LIGHTS is a STREP project within the 6FP. Lights is focused on ovarian cancer and carried
out by a consortium of six partners: University of Modena and Reggio Emilia (I) - University di Paris Sud (FR)
European Media Laboratories (D) - Molecular Discovery (I) - Naxospharma (I) - University of California San Francisco (UCSF)

 
Realized by Newlogic